Camurus AB (publ) (CAMRF) Q2 2026 Earnings Call Transcript

Camurus reported Q2 2026 total revenues of SEK 702m, up 4% year-on-year and 32% sequentially, with an operating result of SEK 293m (42% operating margin). Product sales reached a record SEK 528m (first time above SEK 0.5bn in a quarter), while Buvidal grew 12% y/y and 24% q/q. The company also ended the quarter with SEK 4.1bn in cash, alongside a 42% year-on-year increase in U.S. Brixadi royalties and continued launch progress for Oczyesa.

Analysis

The incremental signal is less about the headline beat and more about mix: CAMRF is showing that once the commercial base is in place, marginal growth converts hard into cash. That matters because the market tends to underwrite these names on pipeline optionality, but the current setup increasingly looks like a cash compounder with multiple shots on goal. If the royalty stream and the in-market product continue compounding, forward estimates should rise faster than consensus revenue, which usually supports both EV/EBITDA and FCF yield re-rating.

Second-order, the strongest competitive read-through is to legacy treatment paradigms that rely on frequent dosing and lower adherence. Long-acting formulations can take share unevenly at first, then accelerate once prescriber habit changes; that typically shows up with a lag of 1-3 quarters, not instantly. The bigger watch item is whether this becomes a broader platform story: if the new launch keeps scaling, partners and potential licensors may start paying up for Camurus-delivered assets, which would improve future deal economics beyond the current product set.

The main risk is that one strong quarter after a soft start is still not proof of a durable inflection. Sell-through, reimbursement stability, and launch spend are the key next data points; if the next quarter does not hold high-single/low-double digit growth or margin slips back below the low-40s, the market will likely fade the re-rate. Over 6-18 months, the thesis breaks if competitive injectables or payer pressure cap uptake, especially in the U.S. where royalty growth needs to stay ahead of normalization.

Consensus may be missing how much of the upside is already self-funding: with a large cash buffer and high operating leverage, CAMRF does not need heroic top-line growth to expand value. The move may actually be underdone if investors are still treating it as a lumpy biotech rather than a de-risking commercial platform.

Key Decisions for Investors

• Add to CAMRF on any post-print weakness over the next 3-5 trading sessions; base case is a 10-15% upside re-rating over 3-6 months if the next quarter confirms sequential growth and margin holds above ~40%.
• Use a tight falsifier: reduce exposure if the next reported quarter shows revenue growth below mid-single digits or operating margin falls materially below 38%, which would suggest the rebound was timing-driven rather than structural.
• Pair trade: long CAMRF / short INDV over 1-3 months as a way to express broader adoption of long-acting addiction therapies while hedging single-name execution risk; thesis works best if U.S. injectable MAT growth continues and CAMRF royalties remain strong.